Clinical Study
Are Breast Cancer Molecular Classes Predictive of Survival in Patients with Long Follow-Up?
Table 1
Clinical-pathological parameters and immunohistochemistry results of the BC cohort (
) and with respect to lymph node involvement.
| | Features | Entire cohort (305) n (%) | LN− (151) n (%) | LN+ (154) n (%) | P |
| | Mean age, years | 46.9 | 46.8 | 47.0 | 0.2 | | (range) | (26–55) | (32–55) | (26–55) | | Age, years | | | | | | ≤35 | 21 (7) | 4 (3) | 17 (11) | 0.004* | | >35 | 284 (93) | 147 (97) | 137 (89) | | Histology | | | | | | Ductal | 250 (83) | 117 (77) | 136 (88) | 0.001* | | Lobular | 28 (9) | 13 (9) | 15 (10) | | Medullary | 6 (2) | 6 (4) | 0 | | Mucinous | 7 (2) | 4 (3) | 3 (2) | | Tubular | 12 (4) | 11 (7) | 0 | | Grade | | | | | | 1 | 39 (13) | 34 (22) | 5 (3) | 0.000* | | 2 | 145 (47) | 86 (57) | 59 (38) | | 3 | 121 (40) | 31 (21) | 90 (59) | | Tumor size, cm | | | | | | ≤2 | 181 (60) | 109 (72) | 72 (48) | 0.000* | | 2–5 | 106 (35) | 39 (26) | 67 (44) | | ≥5 | 15 (5) | 3 (2) | 12 (8) | | Missing | 3 | 0 | 3 | | Lymph nodes | | | | | | 1–3 lymph nodes | 97 (63) | 0 | 97 (63) | | ≥4 lymph nodes | 56 (37) | 0 | 56 (37) | | Missing | 1 | 0 | 1 | | Stage | | | | | | I | 107 (35) | 107 (71) | 0 | | II | 125 (41) | 42 (28) | 83 (54) | | III | 72 (24) | 2 (1) | 70 (46) | | Missing | 1 | 0 | 1 | | Type of surgery | | | | | | Mastectomy | 221 | 88 | 133 | 0.001* | | Breast conservation | 84 | 63 | 21 | | Recurrence | | | | | | No | 143 (49) | 98 (67) | 45 (31) | 0.000* | | Yes | 147 (51) | 49 (33) | 98 (69) | | Missing | 15 | 4 | 11 | | BC specific death | 128 (42) | 39 (26) | 89 (58) | 0.000* | | Living | 143 (47) | 99 (65) | 44 (28) | | Other cause death | 16 (5) | 7 (5) | 9 (6) | | Lost at FU | 18 (6) | 6 (4) | 12 (8) | | ER | | | | | | Negative | 63 (21) | 25 (17) | 38 (25) | 0.08 | | Positive | 242 (79) | 126 (83) | 116 (75) | | PR | | | | | | Negative | 81 (27) | 27 (18) | 54 (35) | 0.001* | | Positive | 224 (73) | 124 (82) | 100 (65) | | HER2 | | | | | Negative | 244 (80) | 140 (93) | 104 (67) | 0.000* | | Positive | 61 (20) | 11 (7) | 50 (33) | | Ki67 | | | | | | <14% | 156 (51) | 104 (69) | 52 (34) | 0.000* | | ≥14% | 149 (49) | 47 (31) | 102 (66) | | CK8 | | | | | | Negative | 29 (10) | 11 (7) | 18 (12) | 0.3 | | Positive | 276 (90) | 140 (93) | 136 (88) | | CK5/6 | | | | | | Negative | 235 (77) | 109 (72) | 126 (82) | 0.04* | | Positive | 70 (23) | 42 (28) | 28 (18) | | Vimentin | | | | | | Negative | 196 (64) | 106 (70) | 90 (58) | 0.03* | | Positive | 109 (36) | 45 (30) | 64 (42) | | AR | | | | | | Negative | 80 (37) | 29 (30) | 51 (43) | 0.04* | | Positive | 136 (63) | 69 (70) | 67 (57) |
|
|
ER: estrogen receptor, PR: progesterone receptor, HER2: human epidermal growth factor receptor-2, CK8: cytokeratin 8, CK5/6: cytokeratin 5/6, AR: androgen receptor. Statistically significant data.
|
